Irlanda - engleză - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - levofloxacin - film-coated tablet - 250 milligram(s) - fluoroquinolones; levofloxacin

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - nevirapine anhydrous - tablet - 200 milligram(s) - non-nucleoside reverse transcriptase inhibitors; nevirapine

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - levofloxacin hemihydrate - film coated tablet - 500 milligram - fluoroquinolones

Singapore - engleză - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nevirapine - tablet - 200 mg - nevirapine 200 mg

Singapore - engleză - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nevirapine anhydrous - tablet, extended release - 400 mg - nevirapine anhydrous 400 mg

Malta - engleză - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - nevirapine - tablet - nevirapine 200 mg - antivirals for systemic use

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - levofloxacin hemihydrate - film-coated tablet - 250 milligram(s) - fluoroquinolones; levofloxacin - pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones, - it is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): - acute bacterial sinusitis. - acute exacerbations of chronic bronchitis. - community-acquired pneumonia. - complicated skin and soft tissue infections

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

stat rx usa llc - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen delayed-release tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administratio

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

h.j. harkins company, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen delayed-release tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administratio

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

rebel distributors corp - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen delayed-release tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administratio